Age: 58.0
Sex: F
Vaccine: COVID19, UNK
Symptoms: COVID-19, SARS-CoV-2 test
Clinical narrative: For 4 days, I took the morning and evening doses. On the 5th day, I took the morning dose but forgot the evening dose. So, I took the final evening dose the next morning, Wednesday. I stayed positive; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (For 4 days, I took the morning and evening doses. On the 5th day, I took the morning dose but forgot the evening dose. So, I took the final evening dose the next morning, Wednesday. I stayed positive) in a 58-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012H21B) for COVID-19 vaccination.    Co-suspect product included non-company product NIRMATRELVIR, RITONAVIR (PAXLOVID) for COVID-19 treatment.    The patient had no allergy.  The patient's past medical history included Partial nephrectomy (left kidney removed) in 2018. Previously administered products included for Product used for unknown indication: Janssen (Dose Number: 1 Batch/Lot No: 1805022 and Location of injection: left arm) on 06-Mar-2021. Past adverse reactions to the above products included No adverse event with Janssen. Concurrent medical conditions included Blood pressure high and Lung opacity (need lung surgery for small ground glass opacity.).   On 22-Dec-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 13-May-2022, the patient started NIRMATRELVIR, RITONAVIR (PAXLOVID) (unknown route) at an unspecified dose. On 22-May-2022, the patient experienced COVID-19 (For 4 days, I took the morning and evening doses. On the 5th day, I took the morning dose but forgot the evening dose. So, I took the final evening dose the next morning, Wednesday. I stayed positive). At the time of the report, COVID-19 (For 4 days, I took the morning and evening doses. On the 5th day, I took the morning dose but forgot the evening dose. So, I took the final evening dose the next morning, Wednesday. I stayed positive) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In May 2022, SARS-CoV-2 test: negative (Negative) Negative. On 22-May-2022, SARS-CoV-2 test: positive (Positive) Positive.         No concomitant medications were reported. It was reported that, for 4 days, she took the morning and evening doses. On the 5th day, took the morning dose but forgot the evening dose. So, took the final evening dose the next morning, Wednesday. She stayed positive until Friday, when tested negative that afternoon. Saturday also tested negative. But Sunday woke up with a sore throat and tested positive. She had typical cold symptoms: stuffy nose, sneezing, sore throat, fatigue. The patient had not received any treatment medication. Company comment: This spontaneous case concerns a 58-year-old, female patient with no relevant medical history, who experienced the unexpected, non-serious of COVID-19. The event occurred 151 days after administration of an unknown dose. On May 22, 2022, SARS-CoV-2 test was done which revealed a positive result, on an unknown date, SARS-CoV-2 test was done which showed a negative result. It has been reported that patient took the medication for 5 days, she experienced sore throat, colds and fatigue. Details of concomitant medications, medical history, clinical course and outcome were not provided. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This spontaneous case concerns a 58-year-old, female patient with no relevant medical history, who experienced the unexpected, non-serious of COVID-19. The event occurred 151 days after administration of an unknown dose. On May 22, 2022, SARS-CoV-2 test was done which revealed a positive result, on an unknown date, SARS-CoV-2 test was done which showed a negative result. It has been reported that patient took the medication for 5 days, she experienced sore throat, colds and fatigue. Details of concomitant medications, medical history, clinical course and outcome were not provided. The benefit-risk relationship of mRNA-1273 is not affected by this report.